Purpose/Objective: To evaluate patterns-of-care and patterns-ofoutcome after stereotactic body radiotherapy (SBRT) for stage I nonsmall cell lung cancer (NSCLC).
No evidence for a learning curve of improved results with larger SBRT experience or practice was observed. Radiation induced pneumonitis grade ≥2 was observed in 7.4% of the patients and grade 5 pneumonitis was documented in only two patients.Thirty day mortality after SBRT was 0.5% (n=3). Conclusions: After irradiation doses ≥106Gy BED, favorable and consistent outcome after SBRT for stage I NSCLC was observed in this multi-institutional analysis despite substantial time-trends and interinstitutional variability in the methodology of SBRT.
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A prospective study to compare doctor versus model predictions for outcome in lung cancer patients: pick the winner! C. Oberije Purpose/Objective: Despite the increasing number of decision making tools, many are not used in daily clinical practice. Implementation might be stimulated if it is obvious that models can offer valuable extra information. We previously reported that prediction models outperformed physicians' predictions based on chart review. However, physically seeing a patient provides the doctor with extra information. The purpose of this prospective study was to compare predictions based on statistical models to predictions made by the physicians after they had seen the patient. Materials and Methods: Based on the performance of already published and validated prediction models for lung cancer, we hypothesized that these models would outperform the doctors prediction by at least 0.1 in Area Under the Curve (AUC) of the ReceiverOperating Characteristic (ROC). The required sample size for the primary outcome, 2-yr survival, was 128 patients. Model predictions were obtained and experienced radiation oncologists were asked to predict 2 year survival,dyspnea (≥grade III) and dysphagia (≥grade III) at two time points: 1) after they had seen the patient for the first visit, and 2) after the treatment plan was made. For survival prediction NSCLC patients,stage I-IIIB, were included;for dyspnea and dysphagia both NSCLC and SCLC were included. All patients were treated with radiotherapy with or without chemotherapy, did not have surgery,no other tumor<5 years ago, and no distant metastasis. We compared the performance of the models to the doctors' in terms of AUC. To gain more insight in the benefit of using predictions in clinical practice we analysed the positive (PPV) and negative predictive value (NPV) for all possible cut-off values of the probabilities. In addition, Kaplan Meier curves based on TNMstage were made. Predictions at time point 2 were only available for 35,39 and 41 patients (survival, dyspnea and dysphagia). Results were in line with those at time point 1. The PPVs of the models were generally higher, while the NPVs of doctors and models were comparable, indicating that the models could better identify high risk patients. Conclusions: Prediction models for lung cancer patients substantially outperformed the physicians' prediction for all outcomes. The difference between doctors and models did not decrease after the doctors had seen the treatment planning. The models were especially superior in identifying high risk patients and should therefore be implemented in clinical practice to guide decisions.
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Reduction of the dose to the elective CTV in HNSCC using IMRT. Dosimetrical analysis and effect on acute toxicity. S. Nuyts Purpose/Objective: Radiation induced toxicity is an important issue in head and neck cancer patients. With the introduction of IMRT into daily practice we are able to minimize doses to organs-at-risk while maintaining adequate tumor coverage. However, the commonly used elective nodal site doses might result in neck fibrosis and dysphagia. The goal of this randomized, multicenter trial was to investigate whether a reduction of the dose to the elective nodal sites and offtarget regions of the swallowing apparatus delivered by IMRT would result in a reduction of both acute and late side effects without compromising tumor control. Materials and Methods: Two-hundred patients with histologically proven head and neck squamous cell carcinoma were randomly assigned to the standard and experimental arm. In the standard arm the elective nodal volumes (PTV elective ) were irradiated up to an equivalent dose of 50Gy in 2 Gy fractions. In the experimental arm an equivalent dose of 40Gy in 2 Gy fractions was delivered to the nodal volumes and the dose to the swallowing apparatus was kept as low as reasonably possible without compromising coverage of the therapeutic PTV (PTV ther ). Toxicity was recorded using CTCAE v3.0 weekly during nd ESTRO Forum 2013 treatment and monthly up until 3 months after finishing treatment. Treatment outcome at 3 and 6 months was retrieved in 131 patients. A two-tailed Fisher's Exact test was used to compare binary data between both arms. A Mann-Whitney U test was performed to compare continuous data. Results: Data of 193 patients could be retrieved (experimental arm: n=96 , standard arm: n= 97). No significant differences between both arms were seen in social status, age, sex, tumor site, smoking and alcohol abuse, TNM stage, performance stage, total dose delivered, overall treatment time and pretreatment dysphagia. Dosimetrically, no significant difference was seen between both arms concerning PTV ther coverage (for D 95 : 67.5 Gy vs 67.3 Gy; p=0.9). As expected the median D 95 of the PTV elect was significantly lower in the experimental arm than in the standard arm (39.5 Gy vs 49.8 Gy; p<0.0001). Using this strategy we were able to significantly reduce the dose to swallowing structures (Table 1) . There was no significant difference in acute mucositis, skin toxicity and weight loss between both groups. During treatment no difference was seen in severe dysphagia. Three months after radiotherapy however there was significantly less grade 3+ dysphagia in the experimental arm compared to the standard arm (2% vs 11%; p=0.03) (Figure 1) . At 6 months, no significant difference was seen in locoregional control between both arms (88% vs 92%; p=0.6). Conclusions: Using IMRT we were able to significantly reduce the dose to the elective nodal volumes and several organs at risk without compromising PTV ther coverage. This resulted in a significant reduction of severe dysphagia 3 months after radiotherapy, without compromising locoregional control. Further follow-up is necessary to investigate whether these observations translate into a benefit on late treatment related dysphagia without affecting treatment outcome. randomised. There were 53, 64 and 62 patients in Arm A, B and C respectively. In arms A and B, all patients received conventional fractionation RT to a total dose of 66-70Gy in 6-7 weeks, five fractions per week. In Arm B, concurrent CT regimen consisted of Cisplatin 30 mg/m2/week. In Arm C, the total dose of radiotherapy was same, 6 fractions were administered per week, with concomitant boost being given on Saturday. Analysis was on an intention-to-treat basis. Results: The median age of cohort was 49 years. The age, sex, primary sites, stage of disease were equally distributed in all three arms. Oropharynx was the most common primary site in all the three arms. The median treatment duration was 49, 51 and 40 days in 3 arms respectively. In arm B, the median number of chemotherapy cycles was 6. The mean and median follow up was 37.7 and 23 months respectively (Inter-quartile range 10-59 months). There was a significant difference in the Disease-Free Survival (DFS) and Overall survival (OS) for CT-RT arm compared with the others. The Median DFS in Arm A was 16 months compared to 34 months in Arm B and 10 months in Arm C (p=0.02). Median OS in Arm A was 32 months compared to 76 months in Arm B and 32 months in Arm C (p=0.05). In terms of acute toxicities patients of Arm A experienced fewer Grade 3 or more oral mucositis compared to Arms B & C (11 versus 22 versus 19 respectively). No incidence of G3 or more haematological toxicity was seen during the treatment in either of the arms. There was no difference in acute grade 3 skin toxicity or significant sequelae between the arms (14 versus 15 versus 10 respectively). In terms of late toxicities (RTOG Scale) G2-G3 xerostomia was similar in all the three arms (10 versus 14 versus 11 respectively). Similarly the late toxicity in terms of skin, mucosa and subcutaneous tissue was similar in the 3 arms. Salvage surgery was done in 19 patients (4 versus 6 versus 9 respectively in Arms A, B & C). Thirteen patients developed second primary cancer (3 versus 5 versus 5 respectively in Arms A, B & C).
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Conclusions: Concurrent CTRT is associated with significant better OS and DFS as compared to RT alone (Conventional or Accelerated) without significant increase in late toxicities. 
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Materials and Methods:
In this phase III multi-site trial, patients with SCC of the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx receiving definitive or adjuvant RT ± chemotherapy were randomised to either institutional standard of care (control) or HUM using the Fisher and Paykel Healthcare MR880 humidifier. HUM commenced day 1 of RT and continued until CTCAE version 3.0 mucositis clinical exam score (CMuc) was <1. Compliance was recorded electronically. HUM Compliance ratio (HCR) was calculated using the formula: total days compliance > 4 hours from RT start to CMuc < grade 1 / total days from RT start to CMuc <grade 1. HCR of > 0.33 was set as the cutoff for the per protocol population analysis (PPA). CMuc was assessed weekly until week 12 or resolution of CMuc score < 1. The primary endpoint was the area under the curve (AUC) of CMuc grade >1. A credentialing programme promoted CMuc scoring consistency among investigators. The secondary endpoint CTCAE v 3.0 mucositis functional score (FSMuc) was analysed with similar methodology. PRO assessments included McMaster University Head and Neck Questionnaire (HRNQ) at baseline, 4, 7,12 and 20 weeks. Symptom cluster questions within HRNQ associated with mucositis analysed in addition to the normal HNRQ domains included severe cluster (difficulty tasting food, clearing secretions, swallowing or chewing) and moderate cluster (low energy, fatigue, dryness mouth, reduced appetite, pain mouth, pain throat, difficulty sleeping). The primary PRO comparison was the difference in means between the 2 arms at each timepoint. Results: 210 patients were randomised (control 105; HUM 105). There was no difference in AUC CMuc means for the intention to treat population (ITT): control 9.0 (95% CI; 8.1 -10.0); HUM 8.9 (95% CI; 8.0 -9.8); p 0.97. When patients with HCR < 0.33 were excluded for the PPA (60HUM patients; 58%), there was again no difference: control 9.0 (8.1 -10.0) HUM 7.8 (6.3 -9.2) p 0.25. There was no difference in AUC FSMuc for ITT: control 9.6 (8.7 -10.4) HUM 8.8 (8.0 -9.5); p 0.22, but a significant difference for PPA: control 9.6 (8.7 -10.4) HUM 7.7 (6.7 -8.7); p 0.009. For HNRQ ITT analysis, there was no difference in outcomes at any timepoint. The HNRQ PPA showed few significant differences but estimates were in the direction that favoured HUM with less symptom severity. Conclusions: There was no difference in the primary endpoint of AUC CMuc with HUM. There is a trend in the HNRQ PPA suggestive of efficacy with HUM which is reflected in the AUC FSMuc PPA as well but the major difficulties in achieving consistent patient compliance suggests this is not an effective therapy for mucositis in its current format. Treatment of patients with oligo-metastasic disease has moved into focus since it has been shown that limited disease volume and sites contribute favorably to outcome. This is also relevant in metastastic lesions to the brain. However, due to the dose-response relationship
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